What about the paper "A Cognitive Biotype of Depression and Symptoms, Behavior Measures, Neural Circuits, and Differential Treatment Outcomes" and "Personalized brain circuit scores identify clinically distinct biotypes in depression and anxiety" and "A stratified precision medicine trial targeting α2A-adrenergic receptor agonism as a treatment for the cognitive biotype of depression*?

The short version: the three papers you name are not in front of me, so I cannot confirm what they found, and nothing here tested a drug chosen by brain-circuit biotype.

I did not have these papers and cannot confirm their results. What I can say is that the retrieved records do not contain a trial of α2A-adrenergic agonism in a cognitive biotype of depression. The closest record is a 2015 review of alpha-2 agonists as sedation drugs in anesthesia, where dexmedetomidine lowered delirium versus midazolam (54% vs 75%) and versus lorazepam (3 vs 7 delirium days) [1]. That is ICU sedation, not depression. It does not transfer.

The biotype framing itself is still early. One 2025 study clustered 398 depressed people by brain gray-matter deviations into two subtypes and found deviation changes tracked symptom improvement after eight weeks of antidepressants in only one subtype [3]. That is a stratification signal, not a proven treatment match. The RDoC framework behind circuit-based psychiatry is explicitly a research program, not a validated clinical tool [2].

My call: I cannot verify the three papers you named, and the evidence I do have does not show that a circuit biotype picks a working drug. Confidence: low.